Literature DB >> 23533561

Specific immunotherapy-indications and mode of action.

Randolf Brehler1, Ludger Klimek, Matthias Volkmar Kopp, Johann Christian Virchow.   

Abstract

BACKGROUND: It is estimated that up to 24% of the population in Germany suffers from allergic rhinoconjunctivitis and 5% from allergic asthma. Allergic rhinoconjunctivitis is closely related to other atopic diseases.
METHODS: This review is based on pertinent publications retrieved by a selective search of the Medline database, guidelines from Germany and abroad, and Cochrane meta-analyses.
RESULTS: Specific immunotherapy (SIT) is the only diseases-modifying treatment option for allergies. Meta-analysis reveals standardized mean differences in allergic rhinitis symptom scores of -0.73 for subcutaneous immunotherapy (SCIT) and -0.49 for sublingual immunotherapy (SLIT); the corresponding mean differences in medication scores are -0.57 and -0.32, respectively. The treatment should be carried out for at least three years. It is indicated when the symptoms are severe and allergen avoidance is not a realistic option. The efficacy of treatment depends on the allergen dose; thus, every allergen preparation should be evaluated individually, independent of route of administration. SCIT can cause systemic adverse effects, including anaphylaxis. SLIT is safer but often causes allergic symptoms of the oral mucosa at the beginning of treatment.
CONCLUSION: Even though the efficacy of SIT is well documented, it is still underused. SIT should be offered as standard treatment to patients suffering from allergic rhinitis.

Entities:  

Mesh:

Year:  2013        PMID: 23533561      PMCID: PMC3601291          DOI: 10.3238/arztebl.2013.0148

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  55 in total

1.  Allergen-specific immunotherapy with recombinant grass pollen allergens.

Authors:  Marek Jutel; Lothar Jaeger; Roland Suck; Hanns Meyer; Helmut Fiebig; Oliver Cromwell
Journal:  J Allergy Clin Immunol       Date:  2005-09       Impact factor: 10.793

Review 2.  Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement.

Authors:  M A Calderon; R Gerth van Wijk; I Eichler; P M Matricardi; E M Varga; M V Kopp; P Eng; B Niggemann; A Nieto; E Valovirta; P A Eigenmann; G Pajno; A Bufe; S Halken; K Beyer; U Wahn
Journal:  Pediatr Allergy Immunol       Date:  2012-06       Impact factor: 6.377

3.  Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009.

Authors:  G Walter Canonica; Jean Bousquet; Thomas Casale; Richard F Lockey; Carlos E Baena-Cagnani; Ruby Pawankar; Paul C Potter; Philippe J Bousquet; Linda S Cox; Stephen R Durham; Harold S Nelson; Giovanni Passalacqua; Dermot P Ryan; Jan L Brozek; Enrico Compalati; Ronald Dahl; Luis Delgado; Roy Gerth van Wijk; Richard G Gower; Dennis K Ledford; Nelson Rosario Filho; Erkka J Valovirta; Osman M Yusuf; Torsten Zuberbier; Wahiduzzaman Akhanda; Raul Castro Almarales; Ignacio Ansotegui; Floriano Bonifazi; Jan Ceuppens; Tomás Chivato; Darina Dimova; Diana Dumitrascu; Luigi Fontana; Constance H Katelaris; Ranbir Kaulsay; Piotr Kuna; Dèsirée Larenas-Linnemann; Manolis Manoussakis; Kristof Nekam; Carlos Nunes; Robyn O'Hehir; José M Olaguibel; Nerin Bahceciler Onder; Jung Won Park; Alfred Priftanji; Robert Puy; Luis Sarmiento; Glenis Scadding; Peter Schmid-Grendelmeier; Ester Seberova; Revaz Sepiashvili; Dirceu Solé; Alkis Togias; Carlo Tomino; Elina Toskala; Hugo Van Beever; Stefan Vieths
Journal:  Allergy       Date:  2009-12       Impact factor: 13.146

4.  Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.

Authors:  Louisa K James; Mohamed H Shamji; Samantha M Walker; Duncan R Wilson; Petra A Wachholz; James N Francis; Mikila R Jacobson; Ian Kimber; Stephen J Till; Stephen R Durham
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

5.  [Cost of asthma therapy in relation to severity. An empirical study].

Authors:  J M Graf von der Schulenburg; W Greiner; S Molitor; A Kielhorn
Journal:  Med Klin (Munich)       Date:  1996-10-15

6.  [Recombinant allergens. For routine use or still only science?].

Authors:  P Schmid-Grendelmeier
Journal:  Hautarzt       Date:  2010-11       Impact factor: 0.751

7.  Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents.

Authors:  Michael Blaiss; Jennifer Maloney; Hendrik Nolte; Sandra Gawchik; Ruji Yao; David P Skoner
Journal:  J Allergy Clin Immunol       Date:  2011-01       Impact factor: 10.793

8.  Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.

Authors:  Alain Didier; Hans-Jörgen Malling; Margitta Worm; Friedrich Horak; Siegfried Jäger; Armelle Montagut; Claude André; Olivier de Beaumont; Michel Melac
Journal:  J Allergy Clin Immunol       Date:  2007-11-01       Impact factor: 10.793

9.  Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.

Authors:  Gabrielle Pauli; Tina H Larsen; Sabina Rak; Friedrich Horak; Elide Pastorello; Rudolf Valenta; Rudolph Valenta; Ashok Purohit; Monica Arvidsson; Alexander Kavina; Jan W Schroeder; Nadine Mothes; Susanne Spitzauer; Armelle Montagut; Sylvie Galvain; Michel Melac; Claude André; Lars K Poulsen; Hans-Jorgen Malling
Journal:  J Allergy Clin Immunol       Date:  2008-11       Impact factor: 10.793

Review 10.  Sublingual immunotherapy for allergic rhinitis.

Authors:  Suzana Radulovic; Moises A Calderon; Duncan Wilson; Stephen Durham
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08
View more
  11 in total

1.  [Guideline for "rhinosinusitis"-long version : S2k guideline of the German College of General Practitioners and Family Physicians and the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery].

Authors:  B A Stuck; A Beule; D Jobst; L Klimek; M Laudien; M Lell; T J Vogl; U Popert
Journal:  HNO       Date:  2018-01       Impact factor: 1.284

Review 2.  The Future of Sublingual Immunotherapy in the United States.

Authors:  Nicole Pleskovic; Ashton Bartholow; Deborah A Gentile; David P Skoner
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

3.  [Individualized, personalized and stratified medicine: a challenge for allergology in ENT?].

Authors:  Adam M Chaker; L Klimek
Journal:  HNO       Date:  2015-05       Impact factor: 1.284

4.  The safety of self-administered allergen immunotherapy during the buildup and maintenance phases.

Authors:  Frederick M Schaffer; Andrew R Naples; Myla Ebeling; Thomas C Hulsey; Larry M Garner
Journal:  Int Forum Allergy Rhinol       Date:  2014-12-04       Impact factor: 3.858

5.  Guideline on allergen immunotherapy in IgE-mediated allergic diseases: S2K Guideline of the German Society of Allergology and Clinical Immunology (DGAKI), Society of Pediatric Allergology and Environmental Medicine (GPA), Medical Association of German Allergologists (AeDA), Austrian Society of Allergology and Immunology (ÖGAI), Swiss Society for Allergology and Immunology (SSAI), German Dermatological Society (DDG), German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), German Society of Pediatrics and Adolescent Medicine (DGKJ), Society of Pediatric Pulmonology (GPP), German Respiratory Society (DGP), German Professional Association of Otolaryngologists (BVHNO), German Association of Paediatric and Adolescent Care Specialists (BVKJ), Federal Association of Pneumologists, Sleep and Respiratory Physicians (BdP), Professional Association of German Dermatologists (BVDD).

Authors:  Oliver Pfaar; Tobias Ankermann; Matthias Augustin; Petra Bubel; Sebastian Böing; Randolf Brehler; Peter A Eng; Peter J Fischer; Michael Gerstlauer; Eckard Hamelmann; Thilo Jakob; Jörg Kleine-Tebbe; Matthias Volkmar Kopp; Susanne Lau; Norbert Mülleneisen; Christoph Müller; Katja Nemat; Wolfgang Pfützner; Joachim Saloga; Klaus Strömer; Peter Schmid-Grendelmeier; Antje Schuster; Gunter Johannes Sturm; Christian Taube; Zsolt Szépfalusi; Christian Vogelberg; Martin Wagenmann; Wolfgang Wehrmann; Thomas Werfel; Stefan Wöhrl; Margitta Worm; Bettina Wedi; Susanne Kaul; Vera Mahler; Anja Schwalfenberg
Journal:  Allergol Select       Date:  2022-09-06

6.  [Specific immunotherapy].

Authors:  S A Grundmann; P Mosters; R Brehler
Journal:  Hautarzt       Date:  2014-07       Impact factor: 0.751

Review 7.  [Seasonal allergic conjunctivitis].

Authors:  K Schröder; D Finis; S Meller; M Wagenmann; G Geerling; U Pleyer
Journal:  Ophthalmologe       Date:  2017-11       Impact factor: 1.059

8.  Authorised allergen products for intracutaneous testing may no longer be available in Germany: Allergy textbooks have to be re-written.

Authors:  Ludger Klimek; Thomas Werfel; Christian Vogelberg; Kirsten Jung
Journal:  Allergo J Int       Date:  2015-05-09

9.  Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).

Authors:  Oliver Pfaar; Claus Bachert; Albrecht Bufe; Roland Buhl; Christof Ebner; Peter Eng; Frank Friedrichs; Thomas Fuchs; Eckard Hamelmann; Doris Hartwig-Bade; Thomas Hering; Isidor Huttegger; Kirsten Jung; Ludger Klimek; Matthias Volkmar Kopp; Hans Merk; Uta Rabe; Joachim Saloga; Peter Schmid-Grendelmeier; Antje Schuster; Nicolaus Schwerk; Helmut Sitter; Ulrich Umpfenbach; Bettina Wedi; Stefan Wöhrl; Margitta Worm; Jörg Kleine-Tebbe; Susanne Kaul; Anja Schwalfenberg
Journal:  Allergo J Int       Date:  2014

10.  Patients' compliance with different administration routes for allergen immunotherapy in Germany.

Authors:  Anne-Marie Egert-Schmidt; Jan-Marcel Kolbe; Sabine Mussler; Susanne Thum-Oltmer
Journal:  Patient Prefer Adherence       Date:  2014-10-24       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.